Clearside BioMedical, Inc Stock News

- XIPERE ® -Related Milestones Generated $20 Million in Non-Dilutive Funding in Q4 2021 -

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 244.44% and 95.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is $0.21 (+250.0% Y/Y) and…

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

In last trading session, Clearside Biomedical Inc. (NASDAQ:CLSD) saw 0.4 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $1.59 trading at $0.13 or 8.90% at ring of the bell on the day assigns it a market valuation of $96.12M. That closing price of CLSD’s stock is … Clearside Biomedical Inc. (NASDAQ:CLSD) Is Down -13.11% Over The Past 30 Days: Is There Trouble Ahead? Read More »

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s

ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral presentations on Clearside''s SCS injection platform featuring the SCS Microinjector ® were given at the Bascom Palmer Eye Institute''s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022. Clearside''s presentation, entitled, "The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians" described the preclinical and clinical data demonstrating the methodology and benefits of suprachoroidal delivery. The preclinical data in multiple animal models showed the potential advantages of SCS delivery over intravitreal delivery, the durability potential of small molecule suspensions, and the possible suitability of suprachoroidal delivery for gene therapy. In conjunction with partners, Clearside''s technology is currently being explored in five clinical trials in four indications: neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, uveitic macular edema, and choroidal melanoma. "Suprachoroidal delivery via our SCS Microinjector offers clinicians several potential core benefits for treatment of their patients with back of the eye diseases: targeting of therapy to affected tissues; compartmentalization of therapy to avoid non-diseased tissues; higher bioavailability; and potential longer durability," said Thomas A.

- Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Agents to the Retina and Choroid - - Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Age

Clearside's suprachoroidal space (SCS®) injection platform to be featured at top medical meeting and also at Raymond James Angiogenesis Preview Event Clearside's suprachoroidal space (SCS®) injectio

Clearside Biomedical Inc (CLSD) shares closed today at 0.9% above its 52 week low of $2.21, giving the company a market cap of $139M. The stock is currently down 15.3% year-to-date, down 35.3% over the past 12 months, and down 74.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 38.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2723.8% The company's stock price performance over the past 12 months lags the peer average by 120.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Gainers: Clearside Biomedical (CLSD) +13%, Ebix (EBIX) +7%, Cipher Mining (CIFR) +6%, Array Technologies (ARRY) +5%, Amicus Therapeutics (FOLD) +4%. Losers: Perella Weinberg…

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

Clearside Biomedical, Inc. (NASDAQ:CLSD) – Stock analysts at Wedbush reduced their FY2021 EPS estimates for Clearside Biomedical in a research note issued to investors on Tuesday, December 21st. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($0.43) per share for the year, down from their prior estimate of ($0.42). Wedbush […]

HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD) in a research report report published on Wednesday, Price Targets.com reports. The firm currently has a $10.00 price target on the stock. CLSD has been the subject of several other reports. JMP Securities restated a buy rating and set a $11.00 target price []